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Binding of hormones to their receptors results in formation of
stabilized complexes which interact with specific regions of DNA
(Yamamato and Alberts, 1976). This leads to increased transcrip-
tion of hormone-dependant genes, translation into proteins, and
eventually replication and tumour cell division and growth.
Receptors for sex hormones have been identified in several
‘hormone-dependent’ organs such as breast, endometrium and
prostate (Smith et al, 1975; Walsh and Hicks, 1979; Howell et al,
1984). The presence of hormone receptors has been found to
correlate with a number of clinicopathological factors and may be
of prognostic significance. Furthermore, endocrine manipulation
plays an important role in the treatment of these malignancies.
More recently, receptors for sex hormones, particularly those for
oestrogen, have been described in ‘non-hormone-dependent’
tumours, such as those of the colon, kidney, pancreas and liver
(McClendon et al, 1977; Kune and Hunt, 1984; Kohigashi et al,
1987). Oestrogen (ER) and progesterone receptors (PR) have been
detected in adenocarcinoma of the stomach (Tokunaga et al,
1986). Endocrine manipulation can play an important part in the
treatment of many of these malignancies and gives supportive
evidence to the role of sex hormone receptors in cancer.
The significance of ER and PR in gastric cancer has yet to be
determined. In vitro and in vivo studies have yielded conflicting
data as to the effect of oestradiol on gastric cancer (Furukawa et al,
1982; Nohga et al, 1987; Harrison et al, 1989a). The prognostic
significance of receptor expression is the subject of conflicting
reports and remains unclear (Tokunaga et al, 1986; Yozozaki et al,
1988; Harrison et al, 1991). Clinical studies of the efficacy of
adjuvant endocrine therapy, mainly involving the administration
of tamoxifen, have also been inconclusive, and many studies
too small and poorly controlled (Kitaoka, 1983; Kojima and
Takahashi, 1986; Harrison et al, 1989b). Nevertheless, determina-
tion of sex hormone receptor expression in gastric cancer may play
an important role in the understanding of the biochemical and
pathophysiological behaviour of this disease.
Conventional assays for ER and PR have relied on biochemical
techniques such as dextran-coated charcoal assay, immunohisto-
chemistry (using polyclonal and, more recently, monoclonal anti-
bodies), enzyme immunoassay and radio-ligand binding assay.
The enormous variation in receptor level expression demonstrated
by these assays has consequently shown ranges of between 0%
and 67% of gastric cancers are positive for ER (Wu et al, 1992a;
Ismail et al, 1994) and between 9% and 83% are positive for PR
(Sica et al, 1984; Wu et al, 1992a).
Use of a flow cytometric assay to quantify receptors in gastric
cancer remains relatively untried. Use of this technique has been
developed for the analysis of breast cancer where it has shown
excellent correlation with the radioligand binding assay
(Brotherick et al, 1994).
The aim of this prospective study was to accurately quantify the
expression of ER and PR expression in gastric cancer, as well as
normal gastric mucosa, using two-colour flow cytometry. We have
further examined the relationship between receptor expression and
established prognostic indicators.
MATERIALS AND METHODS
Fifty patients with histologically proven gastric cancer were
recruited for this study. Tissue for analysis was obtained from
either endoscopic biopsies of the gastric tumour or gastrectomy
specimen obtained immediately following surgical resection. A
further ten biopsies were obtained from patients undergoing
routine endoscopy and confirmed as histologically ‘normal’.
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ER and PR standardization with flow cytometry
The method described by Brotherick et al (1994, 1995a) was
used. Incubation of Quantum Simply Cellular beads (QSC, Flow
Cytometry Standards Corp., NC, USA) with an excess of ER- and
PR-conjugated antibody was performed to saturate all binding
sites. The beads were washed with Isoton II (Coulter) and analysed
by flow cytometry on a FACScan flow cytometer (BD) and
analysed with Lysis II software (Becton Dickinson). Four binding
capacity peaks and one blank peak for non-specific binding were
seen on the FL1 histogram. The median fluorescence channel for
each peak was taken, and a regression curve of linear channel
number against binding capacity was constructed and the equation
for the line calculated with Quickcal QSC calibration software
with calibration for non-specific binding. Conversion of known
linear fluorescence channel numbers into binding capacities for
cells labelled with ER or PR could then be performed.
Preparation of cells for flow cytometry
Samples of gastric tissue were finely minced and further disaggre-
gated by passing through a fine wire mesh (50 mm) to form a
single cell suspension. The resulting cell suspension was
centrifuged at 400 g for 10 min and the resulting pellet resus-
pended at a concentration of approximately 1 ´ 106 cells ml–1
lsoton II (Coulter, Luton, UK). Fifty microlitres of cell suspension
were aliquotted into LP10 tubes (SH Scientific, Northumberland,
UK). To each sample, 50 ml of 2% saponin (BDH, in Isoton II) was
added with gentle mixing. Six tubes were prepared for each
sample as follows: (1) unstained control; (2) 2 ml of mouse IgG-2b
FITC isotype control (Coulter); (3) 10 ml of streptavidin–phyco-
erythrin only (SA-PE control; Becton Dickinson, Oxford, UK); (4)
2 ml of anti-cytokeratin LP-34 (DAKO AS, Denmark); (5) 2 ml of
LP-34 antibody plus 2 ml of anti-ER antibody (ER1D5 biotin-
conjugated, DAKO); (6) 2 ml of LP-34 antibody plus 2 ml anti-PR
antibody (NCL-PR, biotin-conjugated; Novocastra, Newcastle
upon Tyne, UK). All samples were mixed, incubated at 4°C for
20 min and then washed with Isoton II containing 1% saponin. To
those cells labelled with biotinylated antibody, 10 ml SA-PE (BD)
was added to the cell pellet as previously described. After incuba-
tion and washing the cell pellet was resuspended in 0.5 ml Isoton
II, and flow cytometry was performed on a FACScan flow
cytometer (BD) using prestored settings.
Analysis by flow cytometry
Data analysis was performed using Lysis II software. Cellular
debris was excluded by a live gate (R1) set on a dot plot of forward
scatter light (FSC) against side scatter (SSC). A minimum of
10 000 events were collected in the gate R1. Cytokeratin-positive
(LP34-positive) cells were further gated (R2) and median fluores-
cence (PE) values determined from the FL2 histogram for SA-PE-
stained (control), ER- and PR-stained cells. Binding capacities for
the cells were calculated from the standardized QSC bead equation
as described above, and receptor status was therefore evaluated as
the number of binding sites per cell. A cut-off value of 3000 sites
per cell was used, with numbers below this regarded as negative
for the receptors. This was determined using earlier published
work comparing the flow cytometric assay with radio-ligand
binding assays in breast carcinoma (Brotherick et al, 1994).
Consistency of staining
A stock solution of gastric cancer cell line AGS (positive for ER
and PR) and fresh lymphocytes (a negative control) were stained
using the method above on three occasions for ER and PR.
Intra-assay reproducibility was confirmed.
Statistical analysis
Statistical analysis was performed using Minitab (release 9.2) soft-
ware. Receptor expression for the groups analysed were expressed
as a median value with 95% confidence intervals (CI). Groups
were compared using Mann–Whitney U-test and significance
assumed for a P-value less than 0.05. Data were displayed as box
plots.
RESULTS
Fifty gastric cancers and ten histologically ‘normal’ stomachs
were analysed by flow cytometry. The mean (s.e.m.) age of the
patients with gastric cancer was 67.9 (1.23) years, and of the
patients with histologically ‘normal’ stomachs was 65.5 (2.04)
years. Of the patients with gastric cancers, 32 were male and 18
female compared with six histologically normal males and four
females.
Hormone receptor expression in tumours vs normal
stomach
Thirty-six tumours (72%) expressed ER compared with seven
(70%) histological ‘normals’. PR were expressed in 47 (94%) of
the tumours and nine (90%) of the ‘normals’. Only two tumours
and one ‘normal’ expressed neither ER nor PR. There were no
significant differences in ER expression on comparing gastric
cancer and ‘normal’ gastric mucosa groups (medians = 8505 and
9529 respectively; CI 7794 to 5976; P = 0.808). The same was
true for PR (medians = 40 552 and 29 331; CI 51 308 to 16 000;
P = 0.496).
Sex difference
Twenty-two tumours from male patients (69%) expressed ER
compared with 14 (78%) from females. Thirty-one tumours from
males (97%) expressed PR compared with 16 (89%) from females.
No significant differences were determined on comparison of ER
(male vs female medians = 10 245 and 6194; CI 5927–7889;
P = 0.977) or PR (male vs female medians = 42 602 and 34 915;
CI 29 104–33 515; P = 0.718) receptor levels.
Grade and stage
Due to the relatively small numbers, grading was limited to two
groups: well-differentiated (including moderately differentiated
tumours) and poorly differentiated (including undifferentiated
tumours). All histological grading was performed by a single
consultant histopathologist using standard histological criteria.
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for the ‘T’ stage, while the ‘N’ stage was simplified to node-
negative (NO) or -positive (N1, N2).
Sixteen tumours were graded as well-differentiated and 34 as
poorly differentiated. Seven tumours were stage T1, four were T2,
23 were T3 and 16 were T4. Thirty-eight tumours had lymph node
metastases, while 12 were node-negative.
No significant differences were demonstrated for ER expression
with respect to tumour grade (well vs poor; medians = 6569 and
9055; CI 8505 to 5519; P = 0.633) or stage. Similarly, expression
of PR with respect to tumour grade (well vs poor; medians =
49 292 and 38 669; CI 32 371 to 32 552; P = 0.649;) and stage
showed no significant difference.
DISCUSSION
Sex hormone receptor status has been reported to be of prognostic
value in gastric cancer, although more recently its value with
respect to both prognosis and therapeutic response to endocrine
therapy has been disputed as already discussed. Conventional
assays for both ER and PR have been inconsistent and subject to
the limitations of the technique used. Cohen et al (1988) described
the use of image cytometry to allow both quantitation and exami-
nation of heterogeneous tumours. We reported the use of ER 1D5
antibody in conjunction with anti-cytokeratin antibody to quantify
the ER status of primary breast cancers by flow cytometry without
the need for fixation and prolonged incubation (Brotherick et al,
1995b).
In this study we have applied this flow cytometric methodology
to the examination of gastric tumour and normal mucosa. We have
demonstrated ER and PR in a greater proportion of gastric cancers
than published to date. Two-colour flow cytometry has already
proven to be an accurate assay for the quantification of ER in
breast cancer using the DAKO ER1D5 biotinylated antibody
(Brotherick et al, 1995a). Use of a cytokeratin ‘gate’ increases the
assay sensitivity as shown in Figures 1 and 2, by exclusion of non-
epithelial cells and debris. The technique has been reported to be
an accurate and quantitative method for determining receptor
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Figure 1 Fluorescence histograms representing staining for cytokeratin (C) and oestrogen receptors (ER). This sample was stained for ER only and shows a
very low median fluorescence due to the inclusion of non-epithelial cells and debris
Figure 2 Fluorescence histograms representing staining for cytokeratin (C) and oestrogen receptors (ER) as before, on the same population of cells.
However, this sample was stained for both ER and C. The addition of a ‘cytokeratin gate’ results in a significant increase in the median fluorescence value (shift
of peak to the right) for ER by the inclusion of only cytokeratin-positive (epithelial-derived) cells and the exclusion of other cells and debrisexpression on tumour cells (Brotherick et al, 1995b) and therefore
offers advantages over immunohistochemistry. In this study we
have shown that the rapid, simple method for hormone receptor
assay can be applied to small biopsies, such as those from preoper-
ative endoscopy. This may be of importance if hormone manipula-
tion forms a part of the adjuvant treatment of gastric cancer.
Our findings support those of Wu et al (1992a), finding no
significant difference in ER or PR expression in gastric cancer
compared with normal gastric mucosa using DCC and EIA assays.
This is in contrast to the data reported by Kojima et al (1991)
which demonstrated expression of ER in gastric cancer, but not in
normal mucosa when measured by immunohistochemistry and
recent data from Singh et al (1997) showing decreased expression
of ER in gastric cancer compared to normal mucosa. Our data
showed no significant difference between receptor-positive and
receptor-negative groups on comparison with sex, tumour grade
and tumour stage. Similarly, the presence or absence of sex
hormone receptors showed no correlation with the prognostic
indicators studied.
On the basis of these results, expression of sex hormone recep-
tors in gastric cancer is of little clinical significance. The role of
hormonal therapies remains unclear despite the finding that
limited (and often uncontrolled) studies have shown benefit with
tamoxifen (Kitaoka, 1983; Kojima and Takahashi, 1986). Our
findings would, however, complement the findings of a large
British study which failed to show any benefit from tamoxifen
therapy (Harrison et al, 1989b). However, the same study also
identified the presence of ER to be an independent prognostic
factor in gastric cancer, and using immunohistochemistry to
examine receptor status, they reported 55.8% of tumours positive
compared to 70% in our study. These discrepancies may well be
explained by the small patient numbers in this study in combina-
tion with a more sensitive method of receptor quantification.
In summary, this study found no significant difference in sex
hormone expression on comparing gastric cancer and normal
mucosa. No correlation between receptor expression and known
prognostic indicators was found. While sex hormone receptors
may play a biological role in tumour growth and development,
routine assay for ER and PR in gastric cancer is at present of no
clinical benefit in the management of the disease.
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